How Compounded Semaglutide Works for Weight Loss

Compounded semaglutide has become one of the most talked-about options in weight management. As supply shortages of brand-name Ozempic and Wegovy persist, compounded versions prepared by licensed pharmacies offer an accessible alternative at a fraction of the cost.

What Is Compounded Semaglutide?

Compounded semaglutide is the same active molecule (semaglutide) as found in Ozempic and Wegovy, but prepared by a licensed compounding pharmacy rather than the original manufacturer (Novo Nordisk). Under FDA guidance, compounding pharmacies can prepare medications when commercially manufactured versions are in shortage.

How It Works in Your Body

Semaglutide mimics the GLP-1 hormone your body naturally produces after eating. When injected weekly, it:

1. Signals fullness to your brain: Acting on the hypothalamus, semaglutide amplifies satiety signals, making you naturally eat less without constant willpower
2. Slows gastric emptying: Food stays in your stomach longer, extending the feeling of satisfaction after meals
3. Reduces food reward signaling: Studies using brain imaging show semaglutide reduces activity in brain regions associated with food cravings
4. Improves insulin sensitivity: Better blood sugar regulation means fewer energy crashes and cravings

Dosing Schedule

For more detail on dose titration, see our [semaglutide dosing schedule guide](/resources/semaglutide-dosing-schedule-titration-guide).

Treatment follows a gradual escalation protocol to minimize side effects:

Your prescribing clinician may adjust this schedule based on your tolerance and response.

Expected Results

Based on published clinical trial data:

• Month 1: 2-4% body weight reduction. Noticeable appetite decrease.
• Month 3: 5-8% body weight reduction. Measurable changes in waist circumference.
• Month 6: 10-15% body weight reduction. Improvements in metabolic markers.
• Month 12+: 15-20% body weight reduction at maintenance dose.

Results are enhanced when combined with moderate dietary improvements and regular physical activity.

Compounded vs. Brand-Name: Key Differences

For a full side-by-side comparison, see [Compounded Semaglutide vs. Ozempic](/resources/compounded-semaglutide-vs-ozempic).

## Safety Considerations

For a detailed breakdown of safety evidence, see [Is Compounded Semaglutide Safe?](/resources/is-compounded-semaglutide-safe)

Compounded medications have not been independently evaluated by the FDA for safety, efficacy, or quality. Common side effects of semaglutide include nausea, reduced appetite, and mild GI discomfort, typically most pronounced during dose escalation and improving over time.

Compounded medications are not FDA-approved or FDA-evaluated for safety, efficacy, or quality. They are prepared by licensed pharmacies under state and federal regulation. Always consult with a healthcare provider before starting any medication.

Frequently Asked Questions

Is compounded semaglutide the same as Ozempic?

Compounded semaglutide is prepared using semaglutide as the active pharmaceutical ingredient (API) by a licensed compounding pharmacy, not the original manufacturer. Compounded medications are not the same as, equivalent to, or substitutes for FDA-approved medications. The delivery device and inactive ingredients may differ.

How is it administered?

Compounded semaglutide is typically administered as a subcutaneous injection once weekly. Your pharmacy will provide injection supplies and instructions.

Who should not take semaglutide?

Semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, or known hypersensitivity to semaglutide. It is not recommended during pregnancy or breastfeeding.

References

1. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. *N Engl J Med.* 2021 Mar. PMID 33567185. [https://pubmed.ncbi.nlm.nih.gov/33567185/](https://pubmed.ncbi.nlm.nih.gov/33567185/)
2. Rubino D, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults with Overweight or Obesity. *JAMA.* 2021 Apr. PMID 33755728. [https://pubmed.ncbi.nlm.nih.gov/33755728/](https://pubmed.ncbi.nlm.nih.gov/33755728/)
3. Wadden TA, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight. *JAMA.* 2021 Apr. PMID 33625476. [https://pubmed.ncbi.nlm.nih.gov/33625476/](https://pubmed.ncbi.nlm.nih.gov/33625476/)
4. Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. *Diabetes Obes Metab.* 2022 Aug. PMID 35441470. [https://pubmed.ncbi.nlm.nih.gov/35441470/](https://pubmed.ncbi.nlm.nih.gov/35441470/)